PEG-MGF

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic peptide and a modified version of the naturally occurring Mechano Growth Factor (MGF), which is an isoform of insulin-like growth factor-1 (IGF-1). It is used in research for its potential in muscle tissue repair and growth by stimulating stem cell proliferation.

Key Benefits

• Supports muscle growth by stimulating muscle stem cells (satellite cells) involved in muscle repair and development.
• Enhances recovery following intense exercise, resistance training, or muscle injury.
• Promotes tissue regeneration by encouraging the repair of damaged muscle fibers.
• Extends activity duration because pegylation increases the peptide’s half-life, allowing it to remain active longer in the body.
• May improve training adaptations by supporting the body’s natural response to muscle stress and mechanical overload.
• Supports lean muscle development when combined with proper training, nutrition, and recovery.

FDA-Approved Uses

⚠️ NOT FDA APPROVED FOR ANY HUMAN INDICATION ⚠️

PEG-MGF has no FDA-approved use. It is an engineered research compound, not found in nature in this form.

Regulatory status (as of May 2026):

• FDA Category 2 bulk drug substance — 503A compounding PROHIBITED
• NOT on the FDA 503A Category 1 Bulks List
• No PCAC review scheduled for PEG-MGF in the July 2026 cohort
• WADA 2026 Prohibited List: S2 — Growth Factors, related substances and mimetics — PROHIBITED AT ALL TIMES
• Detection: Possible via blood analysis; detection time up to 1–2+ weeks given 24–72 hour half-life
• Australia: IGF-1 variants (including MGF) classified as Schedule 4 prescription-only; importation without approval illegal
• Canada: Similar Schedule restrictions

Related compound context:

• MGF (Mechano Growth Factor / IGF-1Ec): Naturally occurring IGF-1 splice variant produced in response to muscle mechanical stress — endogenous; NOT separately FDA-approved as a drug
• PEG-MGF: SYNTHETIC conjugate of MGF + PEG polymer — an engineered modification not found in nature; distinctly different regulatory status

Conditions studied in research (animal / in vitro — no human RCTs):
1. Muscle repair and recovery after injury or intense exercise
2. Muscle wasting / sarcopenia (age-related and disease-related)
3. Duchenne Muscular Dystrophy (animal models)
4. Cachexia (cancer- or disease-related muscle wasting)
5. Lean mass hypertrophy (athletic performance — most common community use)
6. Tendon and ligament repair
7. Bone fracture healing (animal models)
8. Neurogenesis support (brain MGF expression in aging — separate mechanism)

Trade Names in the USA and Manufacturers

No FDA-approved trade name or manufacturer in USA.

Discovery and development:
– MGF (Mechano Growth Factor) first characterized by Prof. Geoffrey Goldspink and colleagues at University College London (UCL) — identified as a mechanosensitive splice variant of IGF-1 produced in response to muscle damage
– PEG-MGF (pegylated version): Developed as an engineering solution to MGF’s extremely short 5–7 minute half-life
– Original research primarily at UCL and collaborating institutions
– No pharmaceutical company has pursued NDA/BLA filing for either MGF or PEG-MGF in the USA

US availability (as of May 2026):
– Grey-market research peptide vendors: Available as lyophilized powder (‘research use only’)
– 503A compounding pharmacies: PROHIBITED (Category 2 restriction)
– Not available through licensed US pharmacies for any indication

Molecular identity:
– PEG-MGF = MGF E-peptide (C-terminal domain of IGF-1Ec splice variant) conjugated to polyethylene glycol (PEG)
– The E-peptide is the unique C-terminal extension of the IGF-1Ec isoform with autonomous biological activity independent of the IGF-1 domain
– PEG chains attached: Typically 2–40 kDa PEG chains (the ‘PEG cloud’)
– MW: Peptide portion ~2,800–3,000 Daltons + PEG chain (~20 kDa typical total conjugate weight)
– Half-life: ~24–72 hours (vs. 5–7 minutes for native MGF — >1,000x extension)
– Native MGF mechanism: Paracrine (local, at site of muscle damage only)
– PEG-MGF mechanism: SYSTEMIC (circulates; reaches satellite cells in multiple muscle groups from single injection)

PEGylation process:
– Covalent attachment of PEG polymer to MGF peptide
– Creates a hydrophilic ‘PEG cloud’ that physically blocks proteolytic enzymes from cleaving the peptide
– Dramatically increases apparent hydrodynamic size → reduces renal glomerular filtration
– Net result: Extended half-life; systemic distribution from SC injection

Dosage

⚠️ No FDA-approved dosing. 503A compounding PROHIBITED. Category 2 restricted.
All protocols from research community only — NOT clinical trial data.

PEG-MGF is NOT used daily — it is used POST-WORKOUT or on recovery days:
The physiological rationale: MGF is naturally released in response to muscle mechanical damage. PEG-MGF mimics this post-exercise release but with extended duration.

Standard community research protocol:

• Dose per injection: 200–300 mcg SC
• Frequency: 2–3 times per week (e.g., Mon/Wed/Fri)
• Timing: Post-workout on training days; recovery days acceptable
• Route: Subcutaneous injection (abdomen, thigh, or directly near target muscle)
• Cycle duration: 5–6 weeks
• Rest period: 4–6 weeks minimum before next cycle

Bilateral dosing option:
Some protocols divide the dose across two injection sites (e.g., bilateral thighs)
for more distributed satellite cell activation

Lower dose protocol:
100–150 mcg SC daily (some experienced users prefer lower daily doses)
Same cycle/rest structure

Combination stacks (research community):
PEG-MGF (post-workout) + IGF-1 LR3 (rest days): Complementary — PEG-MGF activates satellite cells; IGF-1 LR3 supports protein synthesis and differentiation
PEG-MGF + CJC-1295 + Ipamorelin: Adds GH secretagogue for comprehensive anabolic recovery stack
High risk combination — increased IGF-1 pathway stimulation; monitor carefully

Reconstitution:

• Add 1–2 mL Bacteriostatic Water gently to lyophilized vial
• Swirl gently — do not vortex or shake (PEGylated peptides are more fragile)
• Store lyophilized at -20°C; reconstituted at 2–8°C; use within 14–21 days
• PEGylation improves stability vs. native MGF: better heat/enzyme resistance

Pricing

No FDA-approved commercial pricing. Category 2 restricts 503A compounding.

Research peptide vendors (unregulated):
2 mg vial: ~$20–$45
Monthly cost at standard protocol (200 mcg × 3/week × 4 weeks = ~2.4 mg/month):
Approximately $25–$60/month — among the more affordable research peptides per cycle

Note: PEG-MGF is used in cycles (5–6 weeks) not continuously — reducing total annual cost
Annual cost estimate (2 cycles/year): ~$50–$120/year for the peptide itself

Combination stack costs:
PEG-MGF alone: ~$50–$120/year (2 cycles)
With IGF-1 LR3 as complement: Add ~$100–$250/month during cycle
Full anabolic stack (PEG-MGF + CJC-1295 + Ipamorelin): ~$200–$400/month during active cycle

Tips

• WADA S2 PROHIBITED: PEG-MGF is banned at ALL times in and out of competition. Detection is possible via blood analysis for up to 1–2+ weeks due to its 24–72 hour half-life. Do NOT use if subject to anti-doping testing.
• PEG-MGF is NOT a direct anabolic agent in the way testosterone or steroids are. It activates SATELLITE CELLS (muscle stem cells) to expand the progenitor pool — a prerequisite for hypertrophy.
• The systemic distribution of PEG-MGF (vs. native MGF’s local action) is both an advantage and a concern: advantage — one SC injection supports all muscle groups; concern — satellite cells in non-trained, undamaged muscle may be activated unnecessarily, potentially DEPLETING the satellite cell reserve over time with excessive use.
• Cycling is ESSENTIAL: Never use PEG-MGF continuously. The 5–6 week on / 4–6 week off cycle prevents receptor downregulation, satellite cell pool depletion, and potential off-target tissue growth.
• Anti-PEG antibody formation: Repeated dosing of PEGylated compounds can induce immune antibodies against the PEG moiety — a class effect seen with other PEG-drug conjugates. This can cause accelerated blood clearance (ABC phenomenon) on subsequent doses, reducing effectiveness over time. This is a specific risk not shared by non-PEGylated peptides.
• Post-workout timing: Inject PEG-MGF immediately post-workout to mimic the natural post-exercise MGF release pattern. MGF’s physiological role is timed to post-mechanical stress.
• Glucocorticoids INHIBIT PEG-MGF’s growth-promoting effects — avoid concurrent use (including prescription corticosteroids like prednisone).

Side Effects

From preclinical studies and community use — NO human clinical trial safety data:

Animal study safety profile:

• Generally well-tolerated in rodent and other animal models at research doses
• No serious systemic adverse events in animal studies at therapeutic doses
• Molecular biology: PI3K/Akt/PKB phosphorylation confirmed dose-dependently; no unexpected cellular toxicity in treated cells

Commonly reported in community research use:
– Injection site reactions: Pain, redness, swelling (most common; sometimes significant with larger volumes)
– Mild water retention: Occasional; GH-pathway-related fluid retention
– Joint stiffness: Mild; reported by some users
– Fatigue or headaches: Occasional; during initial use

Less common:
– Temporary hypoglycemia: PEG-MGF has modest insulin-sensitizing effects via IGF-1R partial agonism; use caution if prone to hypoglycemia per prescribing notes
– Excessive tissue hypertrophy: Risk at high doses or injection into non-target tissues; requires site-specific dosing discipline

Serious / mechanism-derived concerns:
– Anti-PEG antibody formation (accelerated blood clearance phenomenon):
With repeated cycles, immune response to PEG moiety can develop
→ Antibodies against PEG → accelerated clearance of subsequent doses → reduced efficacy
→ Rare cases: hypersensitivity/anaphylaxis to PEG-conjugated compounds (documented with other PEG-drug conjugates)

– Cancer risk (IGF-1R pathway):
PEG-MGF’s IGF-1 domain signals through IGF-1R — same pathway as IGF-1 LR3
Tumor growth promotion risk is lower than IGF-1 LR3 (E-peptide mechanism is distinct) but cannot be excluded

– Satellite cell pool depletion:
Chronic or excessive stimulation of satellite cell proliferation theoretically exhausts the stem cell reserve
— long-term consequence not characterized in humans

Contraindications

Per available research prescribing references and pharmacological data:

Contraindicated:
– Active malignancy or neoplastic activity: IGF-1R activation promotes cell proliferation — active cancer is a contraindication; intracranial lesions must be inactive before use
– WADA-tested athletes: S2 prohibited at all times — absolute contraindication
– Pregnancy: Animal reproduction studies indicate pregnancy category B precautions; no adequate human studies; use only if clearly needed (from prescribing reference)
– Concurrent glucocorticoids: Inhibit the growth-promoting effect of PEG-MGF — avoid combination

Strong caution:
– Prone to hypoglycemia: Use with caution per prescribing notes — modest insulin-sensitizing/IGF effects
– Severe liver or kidney impairment: PEG-MGF is metabolized primarily in the liver and kidneys; impaired clearance may alter drug exposure
– Previous anti-PEG antibody reactions: If prior allergic reaction to any PEGylated medication, do not use
– Children and adolescents: Not studied; growth plate effects unpredictable

Australia/Canada:
– IGF-1 variants including MGF are Schedule 4 controlled substances
– Importation without valid prescription is illegal in these jurisdictions

Pharmacology

PEG-MGF (Pegylated Mechano Growth Factor) is a synthetic conjugate of the MGF E-peptide (C-terminal domain of the IGF-1Ec splice variant) covalently linked to polyethylene glycol (PEG) polymer chains.

Mechano Growth Factor (MGF) — parent compound:
– Naturally occurring splice variant of the IGF-1 gene, produced specifically in response to mechanical stress or damage in skeletal muscle (and other mechanically stressed tissues)
– Produced through alternative mRNA splicing: Exon 5 insertion creates the IGF-1Ec isoform → processing produces MGF E-peptide + shared mature IGF-1 domain
– Endogenous expression pattern: Appears within 2–6 hours post-exercise/damage; peaks at 2–6 hours; disappears within 60 minutes (extremely local and transient paracrine action)
– Half-life: 5–7 minutes (makes unmodified MGF impractical for therapeutic use)

PEGylation engineering rationale:
– PEG chains (typically ~20 kDa) covalently attached to the MGF peptide
– Creates a hydrophilic ‘PEG cloud’ that sterically shields the peptide from proteolytic enzymes
– Dramatically increases hydrodynamic radius → reduces renal filtration
– Half-life extended from 5–7 minutes → 24–72 hours
– Converts LOCAL paracrine action → SYSTEMIC circulating action
– MW: Peptide ~2,800–3,000 Da + PEG (~20 kDa) = ~23 kDa total conjugate

The E-peptide vs. IGF-1 domain distinction:
– E-peptide: Activates QUIESCENT satellite cells — drives them from G0 into proliferative phase (NEW satellite cells)
– Mature IGF-1 domain: Activates IGF-1R → cell DIFFERENTIATION and PROTEIN SYNTHESIS (existing muscle fibers grow)
– This two-step action makes MGF uniquely effective: First expand the satellite cell pool, then differentiate and grow

Mechanism of action

PEG-MGF acts through two complementary mechanisms from its two functional domains:

1. MGF E-Peptide — Satellite Cell Activation (primary muscle-specific mechanism):
The unique C-terminal E domain of MGF (not present in other IGF-1 splice variants) activates quiescent (G0) muscle satellite cells:
→ E-peptide binds non-IGF-1R receptor(s) on satellite cells (exact receptor identity still being characterized)
→ Drives satellite cells from G0 (quiescent) → G1 → S phase → PROLIFERATION
→ Expands the pool of muscle progenitor cells available for repair and hypertrophy
→ This satellite cell activation is the FIRST essential step in muscle repair/hypertrophy
→ Kandalla et al. (2011, landmark study): MGF E-peptide significantly increases proliferative lifespan of satellite cells from young adults and delays their senescence

2. Mature IGF-1 Domain — Differentiation and Protein Synthesis:
The shared mature IGF-1 domain (present in all IGF-1 isoforms) acts through IGF-1R:
→ IGF-1R activation → PI3K/Akt/mTOR signaling
→ Protein synthesis (mTOR → S6K1, 4E-BP1 → ribosomal biogenesis)
→ DIFFERENTIATION of proliferated satellite cells into myoblasts → fusion with existing muscle fibers
→ Muscle fiber hypertrophy (enlarged cross-sectional area)
→ Inhibits protein breakdown (anti-catabolic via Akt/FOXO signaling)

3. PEGylation Effect on Mechanism:
Native MGF: PARACRINE — acts only at site of mechanical damage (where it was produced)
PEG-MGF: SYSTEMIC — circulates and reaches satellite cells in multiple muscle groups simultaneously
→ Single SC injection can activate satellite cells across the entire musculature
→ Extended half-life (24–72h) prolongs the satellite cell activation window
→ Trade-off: Loses the damage-specific precision of native MGF; may activate satellite cells in undamaged tissue

Result Claims from Different Companies

Prof. Geoffrey Goldspink / University College London (original MGF research group):

– Goldspink et al. (J Anat, 2007): Characterized MGF as the key local repair factor in muscle, produced within hours of mechanical damage; established the two-domain activity model
– Kandalla et al. (2011, Cytotherapy): MGF E-peptide significantly increased proliferative lifespan of satellite cells from young adults; delayed senescence; relevant to aging muscle repair capacity

Preclinical PEG-MGF animal data:
– Rodent muscle hypertrophy models: 15–20% cross-sectional area increases in treated muscles vs. controls (immunohistochemistry-confirmed satellite cell proliferation)
– Anabolic planner reference: Animal studies showing ‘highly effective in stimulating muscle growth and repair’ — described as producing ‘significant gains in lean mass’ in animal models
– Tendon and bone repair: Positive preclinical data in fracture healing and tendon injury models

In vitro molecular data:
– Phospho-immunoblotting confirms IGF-1R activation and dose-dependent PKB/Akt phosphorylation after PEG-MGF treatment
– Real-time PCR showing increased MyoD and myogenin expression (myogenic differentiation markers)

Community reports:
– Performance athletes report: Enhanced recovery between training sessions, improved muscle repair after injury, moderate lean mass improvements over cycles
– Generally described as a ‘recovery peptide’ rather than a direct anabolic

⚠️ KEY LIMITATIONS:

• ALL efficacy data from animal studies and in vitro cell work
• No human clinical RCTs for any indication
• WADA S2 prohibited at all times — use in athletes is illegal under sport regulations
• FDA Category 2 restricted — 503A compounding PROHIBITED
• Anti-PEG antibody risk with repeated cycles
• Long-term satellite cell pool depletion risk not characterized

Disclaimer

This content about “PEG-MGF” is for informational and educational purposes only, is not medical advice, does not replace consultation with a licensed healthcare professional, and affiliate links may result in compensation at no additional cost to you.